While Maryland remains a critical R&D hub for AstraZeneca, Virginia’s selection as the manufacturing cornerstone also highlights the state’s rising prominence in advanced pharmaceutical production, potentially shifting the regional balance in the U.S. biopharma landscape. It’s a shift that Maryland cannot afford.










Recent Comments